Orchid Pharma Allots 4.46 Crore Equity Shares Under Dhanuka Laboratories Amalgamation Scheme

Orchid Pharma Limited has approved the issuance and allotment of 4,45,86,052 fully paid-up equity shares of face value ₹10 each as part of the implementation of the Scheme of Amalgamation involving Dhanuka Laboratories Limited and Orchid Pharma Limited.

The decision was approved by the company’s Board of Directors at its meeting held on August 1, 2026. The amalgamation scheme became effective on July 10, 2026, marking a significant step in the company’s corporate restructuring and integration process.

Key Share Allotment Details

• Total Equity Shares Allotted: 4,45,86,052 fully paid-up equity shares
• Face Value: ₹10 per equity share
• Purpose of Allotment: Issued pursuant to the Scheme of Amalgamation of Dhanuka Laboratories Limited with Orchid Pharma Limited
• Eligible Shareholders: Equity shareholders of Dhanuka Laboratories Limited whose names appeared on the record date of July 23, 2026
• Rights of New Shares: The newly allotted shares shall rank pari passu with the existing equity shares of Orchid Pharma in all respects.
• Proposed Listing: The shares will be listed and admitted for trading on BSE Limited and the National Stock Exchange of India Limited (NSE), subject to the necessary approvals.

Revised Share Capital

Following the allotment of new equity shares and the cancellation of the existing cross-holding held by Dhanuka Laboratories Limited, Orchid Pharma’s capital structure has been revised as follows:

• Revised Paid-up Equity Share Capital: ₹59,88,52,000
• Total Outstanding Equity Shares: 5,98,85,200 equity shares of face value ₹10 each

Strategic Significance

The allotment represents a key milestone in the implementation of the amalgamation scheme and completes an important phase of Orchid Pharma’s corporate restructuring. The merger is expected to simplify the group’s ownership structure, improve operational integration, and create a more streamlined corporate framework for future growth.

With the amalgamation now substantially implemented, Orchid Pharma is expected to benefit from enhanced organizational efficiency, stronger governance, and better alignment of business operations under a unified corporate structure.